Name | Number of supported studies | Average coverage | |
---|---|---|---|
natural killer cell | 37 studies | 39% ± 22% | |
CD16-negative, CD56-bright natural killer cell, human | 17 studies | 56% ± 18% | |
CD16-positive, CD56-dim natural killer cell, human | 15 studies | 31% ± 15% | |
gamma-delta T cell | 11 studies | 26% ± 7% | |
mature NK T cell | 9 studies | 37% ± 16% | |
innate lymphoid cell | 5 studies | 44% ± 15% | |
CD8-positive, alpha-beta T cell | 4 studies | 23% ± 3% | |
effector memory CD8-positive, alpha-beta T cell | 3 studies | 22% ± 2% | |
T cell | 3 studies | 18% ± 2% |
Insufficient scRNA-seq data for expression of KLRC1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 99% | 88.84 | 572 / 578 | 27% | 0.65 | 311 / 1155 |
thymus | 93% | 39.28 | 605 / 653 | 22% | 0.49 | 132 / 605 |
stomach | 94% | 62.40 | 336 / 359 | 14% | 0.28 | 41 / 286 |
spleen | 100% | 222.37 | 241 / 241 | 0% | 0 | 0 / 0 |
uterus | 61% | 16.58 | 104 / 170 | 35% | 1.05 | 162 / 459 |
prostate | 91% | 39.76 | 222 / 245 | 4% | 0.07 | 22 / 502 |
esophagus | 69% | 18.11 | 1002 / 1445 | 25% | 0.56 | 46 / 183 |
bladder | 71% | 35.48 | 15 / 21 | 17% | 0.70 | 84 / 504 |
intestine | 73% | 37.38 | 702 / 966 | 12% | 0.24 | 65 / 527 |
breast | 70% | 25.01 | 321 / 459 | 14% | 0.35 | 160 / 1118 |
liver | 77% | 18.73 | 173 / 226 | 4% | 0.08 | 17 / 406 |
peripheral blood | 78% | 97.74 | 725 / 929 | 0% | 0 | 0 / 0 |
adipose | 77% | 23.40 | 924 / 1204 | 0% | 0 | 0 / 0 |
pancreas | 58% | 11.79 | 189 / 328 | 17% | 0.33 | 30 / 178 |
kidney | 52% | 11.76 | 46 / 89 | 15% | 0.28 | 131 / 901 |
blood vessel | 56% | 16.28 | 745 / 1335 | 0% | 0 | 0 / 0 |
brain | 46% | 14.27 | 1203 / 2642 | 6% | 0.37 | 43 / 705 |
tonsil | 0% | 0 | 0 / 0 | 51% | 1.16 | 23 / 45 |
lymph node | 0% | 0 | 0 / 0 | 48% | 1.37 | 14 / 29 |
ovary | 34% | 6.74 | 61 / 180 | 10% | 0.22 | 44 / 430 |
heart | 31% | 5.46 | 270 / 861 | 0% | 0 | 0 / 0 |
adrenal gland | 28% | 4.40 | 71 / 258 | 3% | 0.10 | 6 / 230 |
skin | 11% | 1.37 | 193 / 1809 | 16% | 0.40 | 74 / 472 |
muscle | 6% | 0.70 | 49 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0045954 | Biological process | positive regulation of natural killer cell mediated cytotoxicity |
GO_0045087 | Biological process | innate immune response |
GO_0002769 | Biological process | natural killer cell inhibitory signaling pathway |
GO_0001915 | Biological process | negative regulation of T cell mediated cytotoxicity |
GO_0002223 | Biological process | stimulatory C-type lectin receptor signaling pathway |
GO_0002250 | Biological process | adaptive immune response |
GO_0045953 | Biological process | negative regulation of natural killer cell mediated cytotoxicity |
GO_0002305 | Biological process | CD8-positive, gamma-delta intraepithelial T cell differentiation |
GO_0032814 | Biological process | regulation of natural killer cell activation |
GO_0007166 | Biological process | cell surface receptor signaling pathway |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0043235 | Cellular component | receptor complex |
GO_0005886 | Cellular component | plasma membrane |
GO_0004888 | Molecular function | transmembrane signaling receptor activity |
GO_0062082 | Molecular function | HLA-E specific inhibitory MHC class Ib receptor activity |
GO_0030246 | Molecular function | carbohydrate binding |
GO_0023024 | Molecular function | MHC class I protein complex binding |
GO_1990405 | Molecular function | protein antigen binding |
GO_0062080 | Molecular function | inhibitory MHC class Ib receptor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | KLRC1 |
Protein name | NKG2-A NKG2-A/NKG2-B type II integral membrane protein (CD159 antigen-like family member A) (NK cell receptor A) (NKG2-A/B-activating NK receptor) (CD antigen CD159a) Killer cell lectin like receptor C1 |
Synonyms | NKG2A |
Description | FUNCTION: Immune inhibitory receptor involved in self-nonself discrimination. In complex with KLRD1 on cytotoxic and regulatory lymphocyte subsets, recognizes non-classical major histocompatibility (MHC) class Ib molecule HLA-E loaded with self-peptides derived from the signal sequence of classical MHC class Ia molecules. Enables cytotoxic cells to monitor the expression of MHC class I molecules in healthy cells and to tolerate self . Upon HLA-E-peptide binding, transmits intracellular signals through two immunoreceptor tyrosine-based inhibition motifs (ITIMs) by recruiting INPP5D/SHP-1 and INPPL1/SHP-2 tyrosine phosphatases to ITIMs, and ultimately opposing signals transmitted by activating receptors through dephosphorylation of proximal signaling molecules . Key inhibitory receptor on natural killer (NK) cells that regulates their activation and effector functions . Dominantly counteracts T cell receptor signaling on a subset of memory/effector CD8-positive T cells as part of an antigen-driven response to avoid autoimmunity . On intraepithelial CD8-positive gamma-delta regulatory T cells triggers TGFB1 secretion, which in turn limits the cytotoxic programming of intraepithelial CD8-positive alpha-beta T cells, distinguishing harmless from pathogenic antigens . In HLA-E-rich tumor microenvironment, acts as an immune inhibitory checkpoint and may contribute to progressive loss of effector functions of NK cells and tumor-specific T cells, a state known as cell exhaustion . .; FUNCTION: (Microbial infection) Viruses like human cytomegalovirus have evolved an escape mechanism whereby virus-induced down-regulation of host MHC class I molecules is coupled to the binding of viral peptides to HLA-E, restoring HLA-E expression and inducing HLA-E-dependent NK cell immune tolerance to infected cells. Recognizes HLA-E in complex with human cytomegalovirus UL40-derived peptide (VMAPRTLIL) and inhibits NK cell cytotoxicity. .; FUNCTION: (Microbial infection) May recognize HLA-E in complex with HIV-1 gag/Capsid protein p24-derived peptide (AISPRTLNA) on infected cells and may inhibit NK cell cytotoxicity, a mechanism that allows HIV-1 to escape immune recognition. .; FUNCTION: (Microbial infection) Upon SARS-CoV-2 infection, may contribute to functional exhaustion of cytotoxic NK cells and CD8-positive T cells . On NK cells, may recognize HLA-E in complex with SARS-CoV-2 S/Spike protein S1-derived peptide (LQPRTFLL) expressed on the surface of lung epithelial cells, inducing NK cell exhaustion and dampening antiviral immune surveillance . . |
Accessions | ENST00000408006.7 [P26715-2] H0YGB7 ENST00000543893.1 ENST00000347831.9 [P26715-2] Q8NIA5 ENST00000544822.2 [P26715-1] F5GYZ0 P26715 ENST00000359151.8 [P26715-1] ENST00000536188.5 |